Randomized trial · people

Pramlintide: weight loss maintained over 12 months in obesity

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, adding pramlintide to a lifestyle program helped people with obesity lose more weight than placebo and keep it off for a year at two of the dosing schedules, with nausea as the main early side effect.

Kind
Randomized trial
Studied in
People
Number studied
411
Published
2008
Journal
Diabetes Care

What they tested

The team tested how well different pramlintide dosing schedules, added to a lifestyle program, produced and kept off weight loss over 12 months, and how safe they were.

How the study was done

A 4-month double-blind, placebo-controlled trial (placebo, a dummy treatment) randomly assigned 411 people with obesity to placebo or one of six pramlintide arms (120, 240 or 360 microg, given twice or three times a day), all alongside a structured weight-loss lifestyle program. People who could be evaluated at month 4 could continue their assigned treatment in an 8-month single-blind extension focused on keeping weight off, and 77% of them chose to.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At month 4, average weight loss in the pramlintide arms ranged from 3.8 to 6.1 kg, compared with 2.8 kg on placebo. By month 12, the placebo group had regained the weight it lost early on, while every pramlintide arm except 120 microg twice daily held its loss. Compared with placebo, the 120 microg three-times-daily and 360 microg twice-daily arms lost 6.1 kg (5.6% of body weight) and 7.2 kg (6.8% of body weight) more at month 12, and 40% and 43% of those groups lost at least 10% of their weight, versus 12% on placebo. Nausea was the most common side effect in the first 4 months (9-29% on pramlintide vs. 2% on placebo), was mostly mild to moderate, and affected under 10% of people during the extension.

What it doesn’t show

Only 146 people could be evaluated at month 12, and the extension was single-blind and open to those who chose to continue, so the 12-month results come from a smaller, self-selected group. Every participant also followed a structured lifestyle program, so the results apply to pramlintide used together with one.

The paper

Smith et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008.

The compound

More studies on Pramlintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo